查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096915

毒性藥物篩檢市場－全球市場預測（2026-2032年）

Toxicology Drug Screening Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，毒理學藥物篩檢市場將成長至 448.9 億美元，複合年成長率為 9.06%。

主要市場統計數據
基準年 2025 244.5億美元
預計年份：2026年 265.9億美元
預測年份 2032 448.9億美元
複合年成長率 (%) 9.06%

藥物毒理學篩檢已成為臨床診斷、職場藥物檢測、法醫學毒理學、運動醫學、疼痛管理、成癮治療、急診醫學和公共安全計畫中不可或缺的一部分。該領域正超越傳統的濫用藥物檢測，致力於提供更廣泛、更快速、更實證的處方藥、非法藥物、新型精神藥物、酒精生物標記和新興合成藥物的檢測。這項需求的產生源於全球物質使用障礙的沉重負擔、鴉片類藥物相關危害的持續存在、多種物質暴露的日益增多，以及醫療保健、交通運輸、刑事司法和安全關鍵行業日益嚴格的合規要求。現代毒理學工作流程擴大將免疫檢測篩檢與氣相層析法-質譜聯用和液相層析法-串聯式質譜質譜等確證分析技術相結合，以提高分析特異性、減少假陽性結果，並確保結果具有法律效力。同時，尿液、血液、口腔液、毛髮、汗水和乾血斑等檢體類型的選擇也基於其可檢測期、採集便利性、證據管理要求和臨床背景等因素。監管機構和公共衛生機構持續將檢查室品質、檢驗的方法、已記錄的閾值、能力測試和隱私保護放在首位。因此，毒理學篩檢正從被動檢測服務轉向綜合風險管理、臨床決策支援和監測功能，使機構能夠識別暴露模式、制定治療策略、保護職場並加強公共衛生干預措施。

毒理學篩檢領域的變革性變化

毒理學藥物篩檢領域正受到科學、監管和操作層面變革的重塑。其中一項重大變革是從有限的藥物檢測轉向更廣泛、更具針對性的高解析度檢測，這些檢測能夠檢測Fentanyl類似物、合成大麻素、新型苯二氮平類藥物、興奮劑以及其他快速演變的藥物類別。這一轉變尤其重要，因為如果沒有試劑更新或確證試驗，傳統的免疫檢測可能無法可靠地檢測出許多新興物質。實驗室也正在採用更靈活的檢測流程，將初步篩檢、反射性確證試驗和可解釋的報告結合，以提高檢測結果的臨床相關性。另一項顯著變化是，由於口腔拭子採集簡便且篡改風險較低，其在路邊、職場和近期用藥檢測中的應用日益廣泛。同時，尿液檢查因其成熟的操作規程和較長的檢測窗口期而仍然被廣泛使用。毛髮分析繼續用於支持長期接觸評估，而血液檢測在與損傷相關的調查和屍檢研究中仍然發揮著重要作用。數位化證據管理工具、檢查室資訊系統、條碼追蹤和自動化檢體製備正在提高可追溯性和縮短檢測回應時間。在醫療保健領域，毒理學與藥物依從性監測、鴉片類藥物管理、急診決策、新生兒接觸評估和行為健康項目之間的關聯日益緊密。這些變化反映了更廣泛的趨勢，即在臨床和非臨床環境中，毒理學服務正朝著實證檢測、合理解讀和更全面的方向發展。

人工智慧對毒理學篩檢的累積影響

人工智慧正透過簡化工作流程、訊號解讀、異常檢測和決策支援等方式，逐步影響毒理學篩檢。在基於質譜的毒理學領域，人工智慧驅動的分析有助於識別複雜的頻譜模式、確定未知化合物的優先研究方向、輔助資料庫匹配，並加速新型精神藥物的檢測。機器學習模型可以幫助識別結果中的不一致之處、提示檢體篡改的模式、異常的代謝物比例以及處方藥物與檢測到的分析物之間的差異。在高通量檢查室中，人工智慧可以幫助更智慧的批次管理、品管監控、儀器維護預測以及最佳化檢測週轉時間。在臨床環境中，人工智慧驅動的決策支援能夠結合用藥史、診斷代碼、處方療法和風險指標，對藥物檢測結果進行情境化解讀。然而，這些工具需要嚴格的檢驗，以避免可能損害安全性的偏差、過度解讀和自動化。人工智慧的累積影響不會取代合格的毒理學家、實驗室主任或醫學負責人，而是有助於提高分析的一致性並擴大營運規模。負責任的實施需要透明的演算法、檢驗的資料集、審計追蹤、網路安全措施、人工監督以及遵守檢查室標準和隱私法規。隨著藥物趨勢的快速變化，人工智慧驅動的毒理學監測，如果與數據管治和倫理保障措施相結合，還可以幫助公共衛生團隊更早發現新出現的物質。

毒理藥物篩檢的關鍵區域見解

在亞太地區，大規模的醫療保健系統、不斷擴展的診斷基礎設施、交通安全措施和職場合規計劃，以及對合成藥物和處方藥濫用的日益關注，都使得毒理學藥物篩檢的重要性日益凸顯。儘管該地區各國正在加強法醫學和臨床檢查室的能力建設，並在都市區參考檢查室中部署質譜平台，但成熟醫療系統和發展中醫療系統在利用率和標準化方面仍存在顯著差異。在歐洲，重點在於統一的品質標準、法醫學鑑定、交通安全執法、職場安全以及與臨床毒理學的整合，並廣泛使用經認證的實驗室和先進的分析技術。此外，歐洲的監測系統強調了新型精神活性物質的持續湧現，因此需要更新分析資料庫、建立檢驗的閾值，並需要進行跨境可比較報告。北美仍然是毒理學藥物篩檢領域最先進的地區之一，這得益於其完善的職場藥物檢測流程、廣泛的臨床毒理學應用、對鴉片類藥物和Fentanyl的監測需求、完善的刑事鑑定實驗室網路以及對確證性檢測的強勁需求。在該地區，監管機構對檢查室品質、證據儲存和管理、藥物監測以及過量用藥預防的重視持續影響著檢測方案的發展。在拉丁美洲，受跨境毒品販運、都市區安全問題以及檢查室基礎設施現代化需求的推動，毒理學篩檢在公共安全、職業健康、運動檢測和法醫學毒理學領域的應用正在不斷推進。非洲雖然仍處於發展階段，但也是一個重要的市場，毒理學篩檢與法醫學能力建設、道路交通安全、公共衛生監測以及獲得可靠的檢測診斷密切相關。然而，基礎設施和人力資源方面的區域差異仍然是一個主要的阻礙因素。在中東，毒理學藥物篩檢正在機場、職場、法醫學和公共安全計畫中不斷擴大，這得益於對醫療保健現代化、提高檢測能力和加強對管制物質控制的投資。

基於關鍵群體的全球毒理藥物篩檢計畫分析

在北約成員國，毒理學藥物篩檢是保障健康和安全目標的基礎，特別著重於軍事戰備、國防人員篩檢、作戰安全、管制物質政策和互通性標準。七國集團（G7）國家通常在先進分析毒理學、品質保證、與成癮治療的整合、法醫學和數位化檢查室運營方面發揮著主導作用，尤其關注鴉片類藥物、合成藥物、藥物誘發駕駛和藥物依從性監測。在金磚國家，毒理學篩檢的應用呈現多樣化但不斷擴展的趨勢，這主要得益於龐大的人口基數、工業勞動力需求、公共安全優先事項、不斷擴展的臨床診斷以及國內檢測能力的提升。然而，監管成熟度、認證範圍和基礎設施的差異導致了應用路徑的多樣性。歐盟的毒理學格局受到監管協調、資料保護要求、交通安全政策、職場健康法規以及新型精神藥物監測預警系統的影響，因此分析方法的驗證和跨國可比性尤為重要。在東南亞國協，透過公共衛生計畫、海關執法、職場安全措施以及法醫學現代化，藥物篩檢正在加強。雖然先進的檢測技術已在都市區應用，但遍遠地區的檢測服務仍不均衡。在海灣合作理事會國家，勞動合規、邊境管制、航空、交通、醫療保健和法醫學等領域對藥物篩檢的需求十分旺盛。這得歸功於對認證檢測實驗室的投資以及對管制物質的嚴格執法。

影響主要國家引入毒理學篩檢的趨勢

在中國，毒理學篩檢正透過醫院診斷、公共安全、藥物管制、職場檢測以及對先進分析檢查室的投資而不斷擴展。在美國，毒理學篩檢系統已較為成熟，這得益於職場檢測、臨床疼痛管理、成癮治療、急診醫學、法醫學篩檢以及與鴉片類藥物和Fentanyl相關的持續公共衛生挑戰。在日本，重點在於高品質的檢查室操作、職場安全、臨床毒理學、刑事鑑定以及對管制物質的嚴格遵守。在印度，隨著醫療保健、職業健康、法醫學現代化、運動檢測和公共安全計畫的不斷發展，對可靠的篩檢和確認的需求日益成長，毒理學篩檢也在迅速發展。德國的特點是擁有先進的檢測能力、嚴格的品質標準，並在臨床、法醫學、交通和工作場所等領域中廣泛應用。在英國，毒理學篩檢廣泛應用於法醫學、交通安全、職場計畫、醫療和藥物濫用預防服務，並強調經認證的檢測和具有法律效力的解讀。在澳大利亞，成熟的毒理學檢測已應用於職業安全、路邊毒品檢測、採礦、運輸、體育、臨床醫學和法醫學等領域，並輔以嚴格的證據管理（監管鏈）實踐。在法國，毒理學檢測應用於醫療保健、交通安全、職場、法醫學和公共衛生領域，並日益關注新型精神藥物和處方藥的濫用。在韓國，透過法醫學、醫療診斷、職場監測和海關管制，加強了藥物篩檢，並更加關注合成藥物和處方藥的濫用問題。在義大利和西班牙，成熟的毒理學檢測應用領域包括臨床毒理學、交通安全執法、職場計畫、法醫學調查和藥物濫用治療途徑。在加拿大，重點在於減少危害、臨床毒理學、刑事鑑定、職場安全以及對合成鴉片類藥物和多種物質暴露的監測。在俄羅斯，毒理學篩檢環境主要由法醫學、職場要求、交通安全和管制物質監管所驅動。巴西正透過在職場、交通安全、法醫學、體育和臨床領域的應用來提升其毒理學能力，但不同地區的檢查室資源分佈不均。墨西哥的需求則主要來自職業檢測、公共安全、法醫學鑑定以及跨境禁毒等優先事項。

為負責毒理學藥物篩檢的人員提供的實用建議。

產業領導者應優先考慮檢驗且用途適當的毒理學藥物篩檢策略，使檢體類型、檢測窗口、分析物組合和確證試驗與預期用途相符。實驗室和專案管理人員應定期更新檢測組合，以涵蓋Fentanyl類似物、合成大麻素、新型苯二氮平類藥物、興奮劑以及其他可能無法透過常規檢測方法檢測到的新興物質。投資液相層析法-串聯式質譜技術、完善的品管系統、自動化檢體製備系統和安全的實驗室資訊系統可以提高分析可靠性和運作效率。各機構應加強證據管理程序、員工訓練、檢體完整性檢查、記錄閾值、能力測試、由合格人員對結果進行審核。醫療保健專業人員應將毒理學觀察與臨床病史結合，而不是孤立地使用檢測結果，尤其是在疼痛管理、成癮治療、急診醫學和精神科評估方面。職場和公共安全計畫必須在阻礙力和安全目標之間取得平衡，同時制定明確的政策，保障隱私、公平、員工權利和處方藥資訊揭露。領導者在實施人工智慧工具時，必須要求檢驗的證據、可解釋性、稽核日誌、人工監督和網路安全措施。毒理學家、臨床醫生、醫學負責人、合規團隊、法醫學專家和公共衛生機構之間的跨部門協作對於提高解讀準確性、減少錯誤以及快速應對不斷變化的藥物使用模式至關重要。

用於理解毒理學藥物篩檢的調查方法

本執行摘要採用系統性的二手研究方法編寫，以經過檢驗且有數據支持的資訊來源為中心，包括公共衛生機構、監管機構、臨床實驗室標準、同行評審的毒理學文獻、法醫學指南、職業健康框架以及國際公認的藥物監測資源。調查方法強調對多種類型證據進行三角研究途徑，包括分析毒理學的科學論文、免疫檢測測定和質譜分析指南、關於藥物使用和過量用藥模式的公共衛生報告、檢查室認證原則以及與職場、法醫學和臨床實驗室環境相關的監管材料。研究結果評估了其在毒理學藥物檢驗應用領域的相關性，包括臨床診斷、法醫學毒理學、職場檢測、運動檢測、交通安全、藥物依從性和新興藥物篩檢。區域、群體和國家層面的解讀基於已記錄的政策重點、檢查室基礎設施成熟度、醫療保健系統發展、公共安全計劃以及已知的藥物使用挑戰。本分析有意排除市場規模估算、市場規模計算、市場佔有率和預測，而是著重於定性證據、採用促進因素、技術演進、監管考量和營運影響。所有發現均被整合起來，以支持經營團隊決策，同時考慮到不同司法管轄區在法律體制、測試閾值、檢體矩陣和報告標準方面的差異，保持分析上的謹慎性。

結論

隨著醫療機構、雇主、刑事鑑定實驗室和公共機構面臨不斷演變的藥物濫用風險，毒理學篩檢正變得日益複雜、多學科交叉，並具有重要的戰略意義。檢測參數的擴展、確證質譜法的應用、數位化監管鏈、口腔液檢測以及人工智慧分析等技術的進步，正在提升檢測複雜新型藥物暴露的能力。儘管各地部署情況不盡相同，但通用趨勢包括檢查室品質的提高、結果報告速度的加快、合規性的增強以及更具臨床意義的解讀。最成功的項目很可能將科學檢驗的檢測方法與倫理管治、專家評審以及對新出現的藥物威脅的持續適應相結合。對於產業領導者而言，當務之急十分明確：建構一個穩健的毒理學篩檢系統，該系統必須準確、合法、注重隱私，並能支持個人決策和更廣泛的公共衛生資訊。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：毒性藥物篩檢市場：依檢測類型分類

  • 層析法和質譜
    • 氣相層析法和質譜
    • 液相層析法-串聯式質譜質譜法
  • 免疫檢測
  • 分子診斷
    • 次世代定序
    • 基於PCR的檢測
  • 快速檢測

第8章：毒性藥物篩檢市場：依產品類型分類

  • 層析法系統
  • 驗證測試服務
  • 諮詢服務
  • 酵素免疫分析法（ELISA）試劑盒
  • 側向流動免疫檢測試劑盒
  • 質譜儀
  • PCR裝置
  • 篩檢服務

第9章：毒性藥物篩檢市場：依檢體類型分類

  • 血
    • 電漿
    • 全血
  • 頭髮
  • 口腔液
  • 唾液
  • 尿

第10章：毒性藥物篩檢市場：依藥物類別分類

  • 安非他命
  • 苯二氮平類藥物
  • 大麻
  • 古柯鹼
  • 鴉片類藥物

第11章：毒性藥物篩檢市場：依應用領域分類

  • 臨床診斷
  • 刑事鑑定
  • 疼痛管理
  • 體育反興奮劑
  • 職場測試

第12章：毒性藥物篩檢市場：依最終用戶分類

  • 政府/軍事研究所
  • 家庭測試
  • 醫院和診所
  • 獨立檢測實驗室
  • 研究機構

第13章：毒性藥物篩檢市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：毒性藥物篩檢市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 毒理學藥物篩檢市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARK Diagnostics, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Laboratory Corporation of America Holdings
  • LSI Medience Corporation
  • Mediford Corporation
  • Merck KGaA
  • Mindray Bio-Medical Electronics Co., Ltd.
  • Ortho Clinical Diagnostics
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • SGS Group
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • WuXi AppTec
  • Zhejiang Orient Gene Biotech Co.,Ltd.
Product Code: MRR-AD517FAA7D9A

The Toxicology Drug Screening Market is projected to grow by USD 44.89 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.45 billion
Estimated Year [2026] USD 26.59 billion
Forecast Year [2032] USD 44.89 billion
CAGR (%) 9.06%

Toxicology drug screening has become a critical capability across clinical diagnostics, workplace drug testing, forensic toxicology, sports medicine, pain management, addiction treatment, emergency care, and public safety programs. The field is evolving beyond traditional drug-of-abuse testing toward broader, faster, and more defensible detection of prescription medications, illicit substances, novel psychoactive substances, alcohol biomarkers, and emerging synthetic drugs. Demand is being shaped by the global burden of substance use disorders, the persistence of opioid-related harms, rising polysubstance exposure, and stricter compliance expectations in healthcare, transportation, criminal justice, and safety-sensitive industries. Modern toxicology workflows increasingly combine immunoassay screening with confirmatory techniques such as gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry to improve analytical specificity, reduce false positives, and support legally defensible results. At the same time, sample types including urine, blood, oral fluid, hair, sweat, and dried blood spots are being selected based on detection window, collection practicality, chain-of-custody requirements, and clinical context. Regulatory and public health agencies continue to emphasize laboratory quality, validated methods, documented cutoffs, proficiency testing, and privacy safeguards. As a result, toxicology drug screening is moving from a reactive testing service to an integrated risk-management, clinical decision-support, and surveillance function that helps institutions identify exposure patterns, guide treatment, protect workplaces, and strengthen population health interventions.

Transformative Shifts in the Toxicology Drug Screening Landscape

The toxicology drug screening landscape is being reshaped by scientific, regulatory, and operational shifts. One major transformation is the transition from narrow panel testing to expanded, targeted, and high-resolution methods capable of detecting fentanyl analogs, synthetic cannabinoids, designer benzodiazepines, stimulants, and other rapidly changing drug classes. This shift is especially important because conventional immunoassays may not reliably detect many emerging substances without updated reagents or confirmatory testing. Laboratories are also adopting more flexible testing algorithms that combine presumptive screening, reflex confirmation, and interpretive reporting to improve clinical relevance. Another major change is the growing use of oral fluid testing in roadside, workplace, and recent-use detection settings due to observed collection and reduced adulteration risk, while urine remains widely used because of its established protocols and longer detection windows. Hair testing continues to support long-term exposure assessment, and blood testing remains important for impairment-related and postmortem investigations. Digital chain-of-custody tools, laboratory information systems, barcode tracking, and automated sample preparation are improving traceability and turnaround times. In healthcare settings, toxicology is increasingly tied to medication adherence monitoring, opioid stewardship, emergency department decision-making, neonatal exposure assessment, and behavioral health programs. These shifts reflect a broader movement toward evidence-based testing, defensible interpretation, and more integrated toxicology services across clinical and non-clinical environments.

Cumulative Impact of Artificial Intelligence on Toxicology Screening

Artificial intelligence is beginning to influence toxicology drug screening by improving workflow efficiency, signal interpretation, anomaly detection, and decision support. In mass spectrometry-based toxicology, AI-enabled analytics can help identify complex spectral patterns, prioritize unknown compounds for review, support library matching, and accelerate investigation of novel psychoactive substances. Machine learning models can assist in flagging inconsistent results, potential specimen adulteration patterns, unusual metabolite ratios, and discrepancies between prescribed medications and detected analytes. In high-throughput laboratories, AI can contribute to smarter batch management, quality-control monitoring, instrument maintenance prediction, and turnaround-time optimization. In clinical environments, AI-driven decision support can contextualize toxicology results with medication history, diagnosis codes, prescribed therapy, and risk indicators; however, such tools require rigorous validation to avoid bias, overinterpretation, and unsafe automation. The cumulative impact of artificial intelligence is not a replacement for qualified toxicologists, laboratory directors, or medical review officers, but rather an enhancement of analytical consistency and operational scale. Responsible adoption depends on transparent algorithms, validated datasets, audit trails, cybersecurity controls, human oversight, and compliance with laboratory standards and privacy regulations. As drug trends evolve quickly, AI-supported toxicology surveillance may also help public health teams detect emerging substances earlier, provided data governance and ethical safeguards are built into implementation.

Key Regional Insights for Toxicology Drug Screening

Asia-Pacific is experiencing rising relevance for toxicology drug screening as large healthcare systems, expanding diagnostic infrastructure, road safety initiatives, and workplace compliance programs intersect with growing concern over synthetic drugs and prescription medication misuse. Countries in the region are strengthening forensic and clinical laboratory capacity while adopting mass spectrometry platforms in urban reference laboratories, although access and standardization vary widely between mature and developing health systems. Europe emphasizes harmonized quality standards, medico-legal defensibility, road safety enforcement, workplace safety, and clinical toxicology integration, with strong use of accredited laboratories and advanced analytical methods. European monitoring systems have also highlighted the continued emergence of new psychoactive substances, reinforcing the need for updated analytical libraries, validated cutoffs, and comparable reporting across borders. North America remains one of the most advanced regions for toxicology drug screening due to established workplace drug testing practices, extensive clinical toxicology use, opioid and fentanyl surveillance needs, forensic laboratory networks, and strong demand for confirmatory testing. The region's regulatory attention to laboratory quality, chain of custody, medication monitoring, and overdose prevention continues to shape testing protocols. Latin America is seeing increased adoption in public safety, occupational health, sports testing, and forensic toxicology, with demand influenced by cross-border drug trafficking, urban safety concerns, and the need to modernize laboratory infrastructure. Africa presents a developing but important landscape where toxicology screening is linked to forensic capacity building, road traffic safety, public health surveillance, and access to reliable laboratory diagnostics, with uneven infrastructure and workforce availability remaining key constraints. The Middle East is expanding toxicology drug screening through airport, workplace, forensic, and public security programs, supported by investment in healthcare modernization, laboratory capabilities, and strict controlled-substance enforcement.

Key Group Insights Across Global Toxicology Drug Screening Programs

NATO member countries place additional emphasis on military readiness, defense workforce screening, operational safety, controlled-substance policy, and interoperable standards, where toxicology drug screening supports both health protection and security objectives. G7 countries typically lead in advanced analytical toxicology, quality assurance, addiction medicine integration, forensic science, and digital laboratory operations, with heightened focus on opioids, synthetic drugs, impaired driving, and medication adherence monitoring. BRICS economies show varied but expanding adoption, driven by large populations, industrial workforce needs, public safety priorities, clinical diagnostics expansion, and growing domestic laboratory capacity; however, differences in regulatory maturity, accreditation coverage, and infrastructure create diverse implementation pathways. The European Union's toxicology landscape is shaped by regulatory harmonization, data protection requirements, road safety policies, workplace health rules, and early warning systems that monitor new psychoactive substances, making method validation and cross-border comparability especially important. ASEAN countries are strengthening toxicology drug screening through public health programs, customs enforcement, workplace safety measures, and forensic modernization, with urban centers increasingly adopting advanced laboratory methods while rural access remains uneven. The GCC demonstrates strong demand for drug screening in workforce compliance, border control, aviation, transportation, healthcare, and forensic applications, supported by investment in accredited laboratories and strict controlled-substance enforcement.

Key Country Insights Shaping Toxicology Drug Screening Adoption

China is expanding toxicology drug screening through hospital diagnostics, public security, anti-drug enforcement, workplace testing, and investment in advanced analytical laboratories. The United States has a mature toxicology drug screening environment shaped by workplace testing, clinical pain management, addiction treatment, emergency medicine, forensic investigations, and ongoing opioid and fentanyl-related public health challenges. Japan emphasizes high-quality laboratory practices, workplace safety, clinical toxicology, forensic testing, and strict controlled-substance compliance. India's landscape is developing quickly as healthcare expansion, occupational health, forensic modernization, sports testing, and public safety programs increase demand for reliable screening and confirmation. Germany demonstrates advanced laboratory capacity, strict quality expectations, and strong adoption in clinical, forensic, transportation, and occupational settings. The United Kingdom maintains strong use of toxicology drug screening in forensic science, road safety, workplace programs, healthcare, and substance misuse services, with a focus on accredited testing and legally robust interpretation. Australia has well-established toxicology testing in workplace safety, roadside drug testing, mining, transportation, sports, clinical care, and forensic programs, supported by rigorous chain-of-custody practices. France uses toxicology testing across healthcare, road safety, workplace, forensic, and public health contexts, with growing attention to new psychoactive substances and prescription drug misuse. South Korea is strengthening toxicology drug screening through forensic science, healthcare diagnostics, workplace monitoring, customs control, and increased attention to synthetic drugs and prescription medication misuse. Italy and Spain both show established use in clinical toxicology, road safety enforcement, workplace programs, forensic investigations, and substance use treatment pathways. Canada emphasizes harm reduction, clinical toxicology, forensic testing, workplace safety, and monitoring of synthetic opioids and polysubstance exposure. Russia's toxicology screening environment is driven by forensic medicine, workplace requirements, transportation safety, and controlled-substance monitoring. Brazil is advancing toxicology capabilities through workplace, traffic safety, forensic, sports, and clinical applications, while broader laboratory access differs across regions. Mexico's demand is influenced by occupational testing, public safety, forensic needs, and cross-border drug control priorities.

Actionable Recommendations for Toxicology Drug Screening Leaders

Industry leaders should prioritize validated, fit-for-purpose toxicology drug screening strategies that align sample type, detection window, analyte panel, and confirmatory method with the intended use case. Laboratories and program administrators should regularly update testing panels to address fentanyl analogs, synthetic cannabinoids, designer benzodiazepines, stimulants, and other emerging substances that may escape legacy assays. Investment in liquid chromatography-tandem mass spectrometry, robust quality-control systems, automated sample preparation, and secure laboratory information systems can improve analytical confidence and operational efficiency. Organizations should strengthen chain-of-custody procedures, staff training, specimen integrity checks, documented cutoffs, proficiency testing, and result review by qualified professionals. Healthcare providers should integrate toxicology findings with clinical history rather than using results in isolation, especially in pain management, addiction treatment, emergency care, and psychiatric evaluation. Workplace and public safety programs should balance deterrence and safety objectives with privacy, fairness, employee rights, and clear policies on prescription medication disclosure. Leaders adopting AI-enabled tools should require validation evidence, explainability, audit logs, human oversight, and cybersecurity controls. Cross-functional collaboration among toxicologists, clinicians, medical review officers, compliance teams, forensic experts, and public health agencies will be essential to improve interpretation, reduce errors, and respond faster to changing drug-use patterns.

Research Methodology for Toxicology Drug Screening Insights

This executive summary is developed using a structured secondary research approach centered on verified, data-backed sources from public health agencies, regulatory authorities, clinical laboratory standards, peer-reviewed toxicology literature, forensic science guidance, occupational health frameworks, and internationally recognized drug monitoring resources. The methodology emphasizes triangulation across multiple evidence types, including scientific publications on analytical toxicology, guidance on immunoassay and mass spectrometry testing, public health reporting on substance use and overdose patterns, laboratory accreditation principles, and regulatory materials related to workplace, forensic, and clinical testing. Insights are assessed for relevance to toxicology drug screening applications, including clinical diagnostics, forensic toxicology, workplace testing, sports testing, road safety, medication adherence, and emerging drug surveillance. Regional, group, and country-level interpretations are based on documented policy priorities, laboratory infrastructure maturity, healthcare system development, public safety programs, and known substance-use challenges. The analysis intentionally excludes market estimation, market sizing, market share, and forecasting, focusing instead on qualitative evidence, adoption drivers, technology shifts, regulatory considerations, and operational implications. All findings are synthesized to support executive decision-making while maintaining analytical caution around differences in legal frameworks, testing cutoffs, sample matrices, and reporting standards across jurisdictions.

Conclusion

Toxicology drug screening is becoming more sophisticated, multidisciplinary, and strategically important as healthcare providers, employers, forensic laboratories, and public agencies confront evolving substance-use risks. The shift toward expanded panels, confirmatory mass spectrometry, digital chain of custody, oral fluid testing, and AI-supported analytics is improving the ability to detect complex and emerging drug exposures. Regional adoption patterns differ, but the common direction is toward better laboratory quality, faster turnaround, stronger compliance, and more clinically meaningful interpretation. The most successful programs will be those that combine scientifically validated testing methods with ethical governance, skilled human review, and continuous adaptation to new drug threats. For industry leaders, the priority is clear: build resilient toxicology drug screening systems that are accurate, defensible, privacy-conscious, and capable of supporting both individual decision-making and broader public health intelligence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Toxicology Drug Screening Market, by Test Type

  • 7.1. Introduction
  • 7.2. Chromatography & Mass Spectrometry
    • 7.2.1. Gas Chromatography-Mass Spectrometry
    • 7.2.2. Liquid Chromatography-Tandem Mass Spectrometry
  • 7.3. Immunoassay
  • 7.4. Molecular Diagnostics
    • 7.4.1. Next-Generation Sequencing
    • 7.4.2. PCR-Based Testing
  • 7.5. Rapid Testing

8. Toxicology Drug Screening Market, by Product Type

  • 8.1. Introduction
  • 8.2. Chromatography Systems
  • 8.3. Confirmation Services
  • 8.4. Consultation Services
  • 8.5. Enzyme-Linked Immunosorbent Assay Kits
  • 8.6. Lateral Flow Immunoassay Kits
  • 8.7. Mass Spectrometers
  • 8.8. PCR Instruments
  • 8.9. Screening Services

9. Toxicology Drug Screening Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Blood
    • 9.2.1. Plasma
    • 9.2.2. Whole Blood
  • 9.3. Hair
  • 9.4. Oral Fluid
  • 9.5. Saliva
  • 9.6. Urine

10. Toxicology Drug Screening Market, by Drug Class

  • 10.1. Introduction
  • 10.2. Amphetamines
  • 10.3. Benzodiazepines
  • 10.4. Cannabis
  • 10.5. Cocaine
  • 10.6. Opiates

11. Toxicology Drug Screening Market, by Application

  • 11.1. Introduction
  • 11.2. Clinical Diagnostics
  • 11.3. Forensic Testing
  • 11.4. Pain Management
  • 11.5. Sports Anti-Doping
  • 11.6. Workplace Testing

12. Toxicology Drug Screening Market, by End User

  • 12.1. Introduction
  • 12.2. Government & Military Laboratories
  • 12.3. Home Care Testing
  • 12.4. Hospitals & Clinics
  • 12.5. Independent Laboratories
  • 12.6. Research Institutes

13. Toxicology Drug Screening Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Toxicology Drug Screening Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Toxicology Drug Screening Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Agilent Technologies, Inc.
  • 17.3. ARK Diagnostics, Inc.
  • 17.4. Becton, Dickinson and Company
  • 17.5. Bio-Rad Laboratories, Inc.
  • 17.6. Charles River Laboratories International, Inc.
  • 17.7. Danaher Corporation
  • 17.8. Eurofins Scientific SE
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Laboratory Corporation of America Holdings
  • 17.11. LSI Medience Corporation
  • 17.12. Mediford Corporation
  • 17.13. Merck KGaA
  • 17.14. Mindray Bio-Medical Electronics Co., Ltd.
  • 17.15. Ortho Clinical Diagnostics
  • 17.16. PerkinElmer, Inc.
  • 17.17. Quest Diagnostics Incorporated
  • 17.18. SGS Group
  • 17.19. Shimadzu Corporation
  • 17.20. Siemens Healthineers AG
  • 17.21. Sysmex Corporation
  • 17.22. Thermo Fisher Scientific Inc.
  • 17.23. Waters Corporation
  • 17.24. WuXi AppTec
  • 17.25. Zhejiang Orient Gene Biotech Co.,Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHROMATOGRAPHY & MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHROMATOGRAPHY & MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHROMATOGRAPHY & MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PCR-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PCR-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PCR-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RAPID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RAPID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RAPID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHROMATOGRAPHY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONFIRMATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONFIRMATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONFIRMATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONSULTATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONSULTATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONSULTATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LATERAL FLOW IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LATERAL FLOW IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LATERAL FLOW IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SCREENING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SCREENING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SCREENING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AMPHETAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMPHETAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AMPHETAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BENZODIAZEPINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BENZODIAZEPINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BENZODIAZEPINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANNABIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANNABIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANNABIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COCAINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COCAINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COCAINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OPIATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPIATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OPIATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL FORENSIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FORENSIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FORENSIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SPORTS ANTI-DOPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SPORTS ANTI-DOPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SPORTS ANTI-DOPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL WORKPLACE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL WORKPLACE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL WORKPLACE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GOVERNMENT & MILITARY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GOVERNMENT & MILITARY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GOVERNMENT & MILITARY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOME CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOME CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOME CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 192. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 202. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 242. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 279. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 280. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 333. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY & MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (US